Trial Profile
Phase 1/2 study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
- 04 Jun 2019 Results of DGM1 biomarker analysis presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 19 Jan 2010 Actual end ate added as Dec 2009 reported by as reported by ClinicalTrials.gov.
- 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.